COMPANY PROFILE

PamGene

Explore full profile

Offering kinase activity & nuclear receptor solutions in academic research & pharma partnerships

's-Hertogenbosch, NetherlandsFounded 2000Biotech & Life Sciences

Valuation $50–100M Last recorded · 2003

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About PamGene

Provider of novel kinomics platform intended to focus on the measurement of protein activities, with applications in biomarkers for oncology and medicine. The company's platform offers an array of technology, currently focussing on kinases tyrosine and serine-threonine and nuclear receptors, and provides software tools for data analysis, enabling researchers to discover medicines that inhibit or modulate cellular kinases and kinase pathways.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2000
Headquarters: 's-Hertogenbosch, Netherlands
Employees: 48
Open positions: None listed
Dealroom signal: 84.7/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Personal Health, Biotechnology, Nuclear, EIC, Pay Per Result, Biotech and Pharma, Hard Tech, Horizon Europe
Technology: Deep Tech, Nanotech
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn X

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

6 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
GRANT✓Other financing	Mar 2023	$2.5M	—	European Innovation Council	—
GRANT✓Other financing	Jan 2023	$1.1M	—	Undisclosed	↗

Showing the latest 2 of 6 recorded eventsBook a demo for the full funding history →

Growth signals

PamGene website traffic

Latest recorded traffic for PamGene is 70 monthly website visits, down 95% over the last three months. PamGene's team grew 11.6% over the past year.

Latest monthly visits70 3-month web change-95% 1-year team growth+11.6%

Monthly website visitsFeb 2017–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
PTPROSION TherapeuticsPROSION Therapeutics is a drug development company with a proprietary platform that addresses highly unmet medical needs by unlocking undruggables	Cologne, Germany	Operational	6	$2.5M	—
IBInterAx BiotechDelivering High-Quality Drug Candidates for GPCR Targets	Villigen, Switzerland	Operational
HPHerantis PharmaInnovative biotech company developing disease modifying therapies for Parkinson’s disease	Helsinki, Finland	Operational
HTHoba TherapeuticsDeveloper of neuropathic pain and CNS therapies. The company develops biopharmaceuticals for chronic pain and hearing loss	Copenhagen, Denmark	Operational
BTBetalin therapeuticsBetalin's Micro Pancreas is a revolutionary regenerative micro-organ based on cell therapy. It eliminates the need for daily injections, constant blood glucose monitoring, and dietary constraints	Ramat Gan, Israel	Operational
XEXenotheraDeveloping improved immunological treatments using their glyco-humanized antibody platform	Nantes, France	Operational
PEPeptomycFoundational anti-MYC mini-proteins for cancer treatment	Barcelona, Spain	Operational
SESea4UsSea4Us is a biopharmaceutical startup specializing in discovering and developing new drugs, leveraging expertise in ion channels and marine biology	Vila do Bispo, Portugal	Operational